NEW THERAPIES IN UNRESECTABLE PANCREATIC NEUROENDOCRINE TUMORS

Ana-Georgiana Berescu1, Andreea-Mihaela Stoica1, Alexandra Bolocan1,2

1The University of Medicine and Pharmacy “Carol Davila”, Bucharest, Romania
2General Surgery and Emergency Clinic III – The University Emergency Hospital of Bucharest, Romania

Corresponding author: Ana-Georgiana Berescu
Phone no. 0040744963534
E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

Abstract

Until recently, the main form of treatment for the pancreatic neuroendocrine tumors was the surgical resection (the Whipple operation). Due to technological advances, which resulted in more frequent diagnosis, attempts were made to discover other less radical forms of treatment, including limited surgical resection and multiple forms of chemotherapy. Surgical resection has shown benefit only on small lesions with no metastases. According to the recent studies chemotherapeutic agents have shown substantial benefits in terms of survival and disease progression, especially sunitinib and everolimus.

Keywords: pancreatic neuroendocrine tumors, chemotherapy, sunitinib, everolimus

We have 25 guests and no members online

Monday the 23rd.